Park City, UT (PRWEB) March 11, 2015
NuView Life Sciences (NuView), announced that preliminary data presented at the American Urology Association meeting in Baltimore reported the NuView VPAC1 urinary assay achieving over 95% sensitivity for the detection of both prostate and bladder cancers. The results were presented by co-investigator Dr. Eduard Trabulsi from Thomas Jefferson University.
VPAC1 is being developed as a potential pre-biopsy and cytology confirmation test to reduce unnecessary procedures performed and allow improved clinical management and outcomes for men under active surveillance. The precision diagnostic technology was invented by Dr. Mathew Thakur at Thomas Jefferson University in Philadelphia and is under clinical trial development for a number of clinical in-vivo and in-vitro applications. The urinalysis test application targets the VPAC1 protein, which are over expressed on prostate and bladder cancer cells shed in voided urine but not on non-cancerous cells. This proprietary compound specifically targets the cancer cells which illuminate under a microscope, differentiating normal cells from those which have mutated.
“The opportunity to use a precision diagnostic to simplify testing for prostate and bladder cancers is an important benefit for patients and the healthcare industry and a step forward to replacing outdated less accurate technologies as current standards of care,” said NuView Life Sciences CEO Paul Crowe. “We believe that new effective approaches like the NuView VPAC1 test for cancers as opposed to existing PSA blood serum tests or cytology, will ultimately be preferred by physicians and patients and help reduce the more than 1.5 Million negative unnecessary biopsies ordered in the US alone”.
Current screening for prostate cancer is controversial as the U.S. Preventive Services Task Force currently does not recommend routine Prostate Specific Antigen (PSA) tests. Diagnosis of prostate cancer largely depends on histological examinations of prostate tissue with image-guided biopsies. Over 25 million PSA tests are administered annually in the US. Approximately 4 million men exhibit an elevated PSA and approximately 50% of those patients are recommended for a biopsy. Statistics show that approximately 9 out of every 10 biopsies are benign. The same holds true with bladder cancer where FISH and Biopsy and Cytology are the only two tools used to diagnose and monitor bladder cancers. The NuView VPAC1 urine test could greatly reduce the number of cytology procedures resulting in lower health care costs and improved patient outcomes.
About NuView Life Sciences
NuView is a privately held Utah-based biopharmaceutical company whose mission is to identify and develop innovative genomic solutions for the detection and treatment of cancer. The VPAC1 receptor, a member of the vasoactive intestinal peptide receptors (VIPRs), is overexpressed in the most frequently occurring malignant tumors and plays a major role in the progression and angiogenesis of a number of malignancies. NuView and TJU developed a peptide that specifically binds to the VPAC1 receptor only on mutating cells. The NLS-VPAC1 biomarker is a platform technology and has application for in-vivo diagnosis, in-vivo therapeutics and in-vitro urine screening applications. For additional information about NuView Life Sciences, Inc., visit http://www.nuviewinfo.com, http://www.nuviewdx.com.
About Thomas Jefferson University
Thomas Jefferson University (TJU), the largest freestanding academic medical center in Philadelphia, is nationally renowned for medical and health sciences education and innovative research. Founded in 1824, TJU includes Sidney Kimmel Medical College, one of the largest private medical schools in the country and ranked among the nation's best medical schools by U.S. News & World Report, and the Jefferson Schools of Nursing, Pharmacy, Health Professions, Population Health and the Graduate School of Biomedical Sciences. Jefferson University Physicians is TJU's multi-specialty physician practice consisting of the full-time faculty of JMC. Thomas Jefferson University partners with its clinical affiliate, Thomas Jefferson University Hospitals. http://www.jefferson.edu/university.html
NuView Life Sciences
1389 Center Drive, Suite 250
Park City, UT 84098